Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions
Provided By PR Newswire
Last update: Sep 8, 2025
In KRAS mutant 2L mCRC, pelareorep delivers prolonged survival benefit with a median PFS and median OS approximately 2.5x the current standard of care
Translational data from multiple studies confirm pelareorep replication in CRC tumors and immune activation
Read more at prnewswire.comNASDAQ:ONCY (10/31/2025, 3:43:06 PM)
1.175
+0.02 (+1.29%)
Find more stocks in the Stock Screener
